Triamterene

Triamterene is a potassium-sparing diuretic used in the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and other diseases in which edema may occur.

Triamterene passed the animal data screen, underwent a preliminary toxicological evaluation, and is being brought to the Carcinogen Identification Committee for consultation. This is a compilation of the relevant studies identified during the preliminary toxicological evaluation.

Epidemiological data

No cancer epidemiology studies were identified.

Animal carcinogenicity data

- Two-year diet studies in rats
  - Male F344/N rats: NTP (1993)
  - Female F344/N rats: NTP (1993)

- Two-year diet studies in mice
  - First study in male B6C3F₁ mice: NTP (1993)
  - Second study in male B6C3F₁ mice: NTP (1993)
  - First study in female B6C3F₁ mice: NTP (1993)
  - Second study in female B6C3F₁ mice: NTP (1993)

Other relevant data

- Genotoxicity
  - Chinese hamster ovary assay for chromosomal aberrations: ibid
  - Chinese hamster ovary assay for sister chromatid exchanges: ibid
  - Reviews of in vitro and in vivo assays: NTP (1993, pp. 15 and 64)

Reference

National Toxicology Program (NTP, 1993) Technical Report on the Toxicology and Carcinogenesis Studies of Triamterene (CAS No. 396-01-0) in F344/N Rats and B6C3F₁ Mice (Feed Studies). National Toxicology Program, National Institutes of Health, NIH Publication No. 94-3151. NTP TR 420.